We recommend the use of the following pangenotypic DAA regimens in younger children (3–5 years) with chronic hepatitis C infection, regardless of stage of disease: sofosbuvir/daclatasvir (Most widely used regimen in adults due to availability of quality-assured, low-cost generics) for 12 weeks (In those without cirrhosis. Treatment for 24 weeks in those who are treatment-experienced or with compensated cirrhosis), sofosbuvir/velpatasvir for 12 weeks, glecaprevir/pibrentasvir for eight weeks